The global oncology based in-vivo CRO market size was valued at USD 1.19 billion in 2023, driven by the development of non-viral delivery systems across the globe. The market is anticipated to grow at a CAGR of 7.9% during the forecast period of 2024-2032 to achieve a value of USD 2.35 billion by 2032.
Oncology based in-vivo CRO provides specialized services in the field of oncology research. A diverse range of services is provided by this organization in order to support the development of new oncology therapies and treatments. The main services provided by Oncology based In-Vivo CRO are study design, selection and validation of animal model, data collection and analysis, and regulatory compliance, along with dosing and drug administration, and tumor imaging and measurement.
The specialized CROs provide knowledge and experience in the conduct of investigations and tests employing in vivo models, such as animal models, to assess the efficacy and safety of new oncology treatments. Through the use of in vivo tumor models, xenograft and syngeneic models, pharmacokinetic investigations, toxicological analyses, and efficacy studies, in-vivo CROs offer thorough evaluation of potential oncology medications. They aid in finding indicators of therapy response or resistance, helping to test novel cancer therapies, and analyzing how treatments affect tumor growth and metastasis.
Expert services are provided by these organizations due to the access they have to advanced technologies and equipment that are required and necessary to conduct in-vivo studies. The expansion of personalized medicine owing to the market growth. By offering preclinical services that promote the development of targeted medicines and ease the discovery and validation of biomarkers, in-vivo CROs are significantly contributing to the advancement of personalized medicine. Additionally, the field of immuno-oncology harnesses the body's immune system to fight cancer has also been witnessing significant growth, leading to further oncology based in-vivo CRO market expansion.
In-Vivo CROs actively conducting preclinical studies to evaluate the efficacy and safety of immunotherapies and combination therapies to support the immuno-oncology research, propelling the oncology based in-vivo CRO market growth. The increased integration of artificial intelligence and machine learning technologies to improve the quality of data analysis, image processing, and predictive modeling are directly contributing to the market growth. In-Vivo CROs are the technologies that enables better interpretation of complex preclinical data and facilitate the identification of novel biomarkers, improving decision-making processes and accelerating drug discovery efforts.
Market Breakup by Indication
Market Breakup by Model
Market Breakup by Region
The market for oncology based in-vivo CRO has been witnessing evident growth in the past and is expected to see the growth in coming years as well owing to the increasing prevalence of cancer worldwide. The demand for newly developed therapies that are effective and innovative has increased and has created an emphasis on research and development for these therapies in the oncology filed. The demand for cost-effective and time-efficient drug development procedures has also been a driver for market growth.
In-vivo CROs provide specialised knowledge in creating and using animal models that closely resemble the characteristics of human cancers, enabling the assessment of targeted treatments and individualised treatment plans. This is further aiding the oncology based in-vivo CRO market development.
To ensure that only the highest-quality products are let onto the market, health authorities have established strict regulatory restrictions on pharmaceutical businesses. In-Vivo CROs help these companies adhere to these regulations. In-Vivo CROs assist in ensuring that potential oncology treatments meet the requisite safety and efficacy requirements for further development and clinical trials by conducting preclinical research in accordance with Good Laboratory Practise (GLP) standards which directly contributes to the market growth.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Indication
|Breakup by Model
|Breakup by Region
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Oncology Based In-Vivo Cro Market Overview
3.1 Global Oncology Based In-Vivo Cro Market Historical Value (2017-2023)
3.2 Global Oncology Based In-Vivo Cro Market Forecast Value (2024-2032)
4 Global Oncology Based In-Vivo Cro Market Landscape
4.1 Image Guided Surgery: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Image Guided Surgery: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indication
5 Global Oncology Based In-Vivo Cro Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Oncology Based In-Vivo Cro Market Segmentation
6.1 Global Oncology Based In-Vivo Cro Market by Indication
6.1.1 Market Overview
6.1.2 Blood Cancer
6.1.3 Solid Tumors
6.1.4 Other Indications
6.2 Global Oncology Based In-Vivo Cro Market by Model
6.2.1 Market Overview
6.2.4 Patient Derived Xenograft (PDX)
6.3 Global Oncology Based In-Vivo Cro Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Oncology Based In-Vivo Cro Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Oncology Based In-Vivo Cro Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Oncology Based In-Vivo Cro Market
9.1 Market Share by Country
10 Latin America Oncology Based In-Vivo Cro Market
10.1 Market Share by Country
11 Middle East and Africa Oncology Based In-Vivo Cro Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Crown Bioscience Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Charles River Laboratories Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 ICON PLC
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Taconic Biosciences Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5 Covance Inc.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Eurofins Scientific
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 The Jackson Laboratory
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9 Wuxi AppTec.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10 MI Bioresearch Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 1.19 billion in 2023, driven by the increasing demand for newly developed therapies.
The market is anticipated to grow at a CAGR of 7.9% during the forecast period of 2024-2032 to reach a market value of USD 2.35 million by 2032.
The increasing demand for cost-effective and time-efficient drug development procedures are among the key drivers aiding the market growth.
The technological advancement in the imaging process and demand for personalized medicine market are the key trends driving the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The models in the market include syngeneic xenograft and patient derived xenograft (PDX).
The different indications of oncology based In-Vivo CRO include blood cancer, solid tumors, other indications.
Key players involved in the market include Crown Bioscience Inc., Charles River Laboratories Inc., ICON PLC, Taconic Biosciences Inc., Covance Inc., Eurofins Scientific, EVOTEC, The Wuxi AppTec., MI Bioresearch Inc., and Jackson Laboratory.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.